Captopril’s uniformity in low starting dose and subsequent stepwise increases over time can perhaps be attributed to concerns about using ACE inhibitors in preterm infants due to potential adverse effects such as hypotension, acute renal failure, neurological complications, and potential effects on renal maturation [20,30,31]. This evidence concerns the gene ACE and acute kidney injury.